BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 24837142)

  • 1. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation.
    Brodowska K; Al-Moujahed A; Marmalidou A; Meyer Zu Horste M; Cichy J; Miller JW; Gragoudas E; Vavvas DG
    Exp Eye Res; 2014 Jul; 124():67-73. PubMed ID: 24837142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic therapy in retinoblastoma: effects of verteporfin on retinoblastoma cell lines.
    Stephan H; Boeloeni R; Eggert A; Bornfeld N; Schueler A
    Invest Ophthalmol Vis Sci; 2008 Jul; 49(7):3158-63. PubMed ID: 18579764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Photoinduced Biological Properties of Verteporfin.
    Gibault F; Corvaisier M; Bailly F; Huet G; Melnyk P; Cotelle P
    Curr Med Chem; 2016; 23(11):1171-84. PubMed ID: 26980565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Verteporfin inhibits growth of human glioma in vitro without light activation.
    Al-Moujahed A; Brodowska K; Stryjewski TP; Efstathiou NE; Vasilikos I; Cichy J; Miller JW; Gragoudas E; Vavvas DG
    Sci Rep; 2017 Aug; 7(1):7602. PubMed ID: 28790340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of the migration effect and molecular docking of verteporfin in different subtypes of breast cancer cells.
    Wei C; Li X
    Mol Med Rep; 2020 Nov; 22(5):3955-3961. PubMed ID: 32901856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verteporfin inhibits cell proliferation and induces apoptosis in different subtypes of breast cancer cell lines without light activation.
    Wei C; Li X
    BMC Cancer; 2020 Oct; 20(1):1042. PubMed ID: 33121449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verteporfin regulates corneal neovascularization through inhibition of YAP protein activation.
    Lin L; Zheng Y; Li Q; Sun Y; Huang Y; Liang L; Xu L; Zhao YE
    Exp Eye Res; 2024 Jan; 238():109747. PubMed ID: 38072353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Verteporfin, a suppressor of YAP-TEAD complex, presents promising antitumor properties on ovarian cancer.
    Feng J; Gou J; Jia J; Yi T; Cui T; Li Z
    Onco Targets Ther; 2016; 9():5371-81. PubMed ID: 27621651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rabbit model of ocular indirect photodynamic therapy using a retinoblastoma xenograft.
    Kim JW; Jacobsen B; Zolfaghari E; Ferrario A; Chevez-Barrios P; Berry JL; Lee DK; Rico G; Madi I; Rao N; Stachelek K; Wang LC; Gomer C
    Graefes Arch Clin Exp Ophthalmol; 2017 Dec; 255(12):2363-2373. PubMed ID: 28971251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo efficacy of photodynamic therapy in three new xenograft models of human retinoblastoma.
    Aerts I; Leuraud P; Blais J; Pouliquen AL; Maillard P; Houdayer C; Couturier J; Sastre-Garau X; Grierson D; Doz F; Poupon MF
    Photodiagnosis Photodyn Ther; 2010 Dec; 7(4):275-83. PubMed ID: 21112551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway.
    Dong L; Lin F; Wu W; Liu Y; Huang W
    Int J Med Sci; 2018; 15(6):645-652. PubMed ID: 29725256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells.
    Dasari VR; Mazack V; Feng W; Nash J; Carey DJ; Gogoi R
    Oncotarget; 2017 Apr; 8(17):28628-28640. PubMed ID: 28404908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex.
    Wei H; Wang F; Wang Y; Li T; Xiu P; Zhong J; Sun X; Li J
    Cancer Sci; 2017 Mar; 108(3):478-487. PubMed ID: 28002618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Features of the YAP Inhibitor Verteporfin: Synthesis of Hexasubstituted Dipyrrins as Potential Inhibitors of YAP/TAZ, the Downstream Effectors of the Hippo Pathway.
    Gibault F; Bailly F; Corvaisier M; Coevoet M; Huet G; Melnyk P; Cotelle P
    ChemMedChem; 2017 Jun; 12(12):954-961. PubMed ID: 28334506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Molecule-Targeted Therapy and Photodynamic Therapy Using Nanoformulated Verteporfin for Effective Uveal Melanoma Treatment.
    Song M; Zhu L; Zhang L; Ge X; Cao J; Teng Y; Tian R
    Mol Pharm; 2024 May; 21(5):2340-2350. PubMed ID: 38546166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Photoactivated and Non-Photoactivated Verteporfin on Tumor.
    Wei C; Li X
    Front Pharmacol; 2020; 11():557429. PubMed ID: 33178014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Verteporfin without light stimulation inhibits YAP activation in trabecular meshwork cells: Implications for glaucoma treatment.
    Chen WS; Cao Z; Krishnan C; Panjwani N
    Biochem Biophys Res Commun; 2015 Oct; 466(2):221-5. PubMed ID: 26361148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The killing effect of photodynamic therapy using benzoporphyrin derivative on retinoblastoma cell line in vitro.
    Jin C; Wu Z; Li Y; Li Y; Chen H; North J
    Yan Ke Xue Bao; 1999 Mar; 15(1):1-6. PubMed ID: 12579652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models.
    Barrette AM; Ronk H; Joshi T; Mussa Z; Mehrotra M; Bouras A; Nudelman G; Jesu Raj JG; Bozec D; Lam W; Houldsworth J; Yong R; Zaslavsky E; Hadjipanayis CG; Birtwistle MR; Tsankova NM
    Neuro Oncol; 2022 May; 24(5):694-707. PubMed ID: 34657158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines".
    Sanna L; Piredda R; Marchesi I; Bordoni V; Forcales SV; Calvisi DF; Bagella L
    Chem Biol Interact; 2019 Oct; 312():108813. PubMed ID: 31494105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.